Mexico · Delayed Price · Currency is MXN Corpovael Statistics
Total Valuation
Corpovael has a market cap or net worth of MXN 2.12 billion. The enterprise value is 4.04 billion.
| Market Cap | 2.12B |
| Enterprise Value | 4.04B |
Important Dates
The next estimated earnings date is Wednesday, February 24, 2027.
| Earnings Date | Feb 24, 2027 |
| Ex-Dividend Date | Aug 27, 2026 |
Share Statistics
Corpovael has 292.64 million shares outstanding. The number of shares has decreased by -3.02% in one year.
| Current Share Class | 292.64M |
| Shares Outstanding | 292.64M |
| Shares Change (YoY) | -3.02% |
| Shares Change (QoQ) | -0.56% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 4.86 and the forward PE ratio is 5.45.
| PE Ratio | 4.86 |
| Forward PE | 5.45 |
| PS Ratio | 0.36 |
| PB Ratio | 0.36 |
| P/TBV Ratio | 0.36 |
| P/FCF Ratio | 6.40 |
| P/OCF Ratio | 6.32 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.39, with an EV/FCF ratio of 12.00.
| EV / Earnings | 9.24 |
| EV / Sales | 0.68 |
| EV / EBITDA | 6.39 |
| EV / EBIT | 6.54 |
| EV / FCF | 12.00 |
Financial Position
The company has a current ratio of 3.07, with a Debt / Equity ratio of 0.41.
| Current Ratio | 3.07 |
| Quick Ratio | 0.85 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 4.04 |
| Debt / FCF | 7.32 |
| Interest Coverage | 8.58 |
Financial Efficiency
Return on equity (ROE) is 7.56% and return on invested capital (ROIC) is 5.90%.
| Return on Equity (ROE) | 7.56% |
| Return on Assets (ROA) | 2.97% |
| Return on Invested Capital (ROIC) | 5.90% |
| Return on Capital Employed (ROCE) | 5.73% |
| Weighted Average Cost of Capital (WACC) | 2.47% |
| Revenue Per Employee | 38.58M |
| Profits Per Employee | 2.86M |
| Employee Count | 156 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 1.34 |
Taxes
In the past 12 months, Corpovael has paid 123.13 million in taxes.
| Income Tax | 123.13M |
| Effective Tax Rate | 21.61% |
Stock Price Statistics
The stock price has increased by +89.39% in the last 52 weeks. The beta is -0.27, so Corpovael's price volatility has been lower than the market average.
| Beta (5Y) | -0.27 |
| 52-Week Price Change | +89.39% |
| 50-Day Moving Average | 7.39 |
| 200-Day Moving Average | 6.22 |
| Relative Strength Index (RSI) | 54.49 |
| Average Volume (20 Days) | 5,609 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Corpovael had revenue of MXN 6.02 billion and earned 445.71 million in profits. Earnings per share was 1.49.
| Revenue | 6.02B |
| Gross Profit | 1.34B |
| Operating Income | 607.40M |
| Pretax Income | 569.77M |
| Net Income | 445.71M |
| EBITDA | 613.91M |
| EBIT | 607.40M |
| Earnings Per Share (EPS) | 1.49 |
Balance Sheet
The company has 643.80 million in cash and 2.51 billion in debt, with a net cash position of -1.87 billion or -6.38 per share.
| Cash & Cash Equivalents | 643.80M |
| Total Debt | 2.51B |
| Net Cash | -1.87B |
| Net Cash Per Share | -6.38 |
| Equity (Book Value) | 6.07B |
| Book Value Per Share | 20.56 |
| Working Capital | 4.27B |
Cash Flow
In the last 12 months, operating cash flow was 347.20 million and capital expenditures -4.23 million, giving a free cash flow of 342.98 million.
| Operating Cash Flow | 347.20M |
| Capital Expenditures | -4.23M |
| Depreciation & Amortization | 6.50M |
| Net Borrowing | 311.41M |
| Free Cash Flow | 342.98M |
| FCF Per Share | 1.17 |
Margins
Gross margin is 22.25%, with operating and profit margins of 10.09% and 7.41%.
| Gross Margin | 22.25% |
| Operating Margin | 10.09% |
| Pretax Margin | 9.47% |
| Profit Margin | 7.41% |
| EBITDA Margin | 10.20% |
| EBIT Margin | 10.09% |
| FCF Margin | 5.70% |
Dividends & Yields
This stock pays an annual dividend of 0.38, which amounts to a dividend yield of 5.24%.
| Dividend Per Share | 0.38 |
| Dividend Yield | 5.24% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 24.95% |
| FCF Payout Ratio | 32.42% |
| Buyback Yield | 3.02% |
| Shareholder Yield | 8.09% |
| Earnings Yield | 20.56% |
| FCF Yield | 15.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Corpovael is 8.50, which is 17.24% higher than the current price. The consensus rating is "Buy".
| Price Target | 8.50 |
| Price Target Difference | 17.24% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 6.27% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Corpovael has an Altman Z-Score of 1.7 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.7 |
| Piotroski F-Score | 5 |